Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.31
    OpenPayerPolicy UpdatesGastroenterologyCentene RELiZORB Coverage Prior Auth | OpenPayer
    Ask Trek AI about this page
    CurrentCentenePolicy CP.MP.252

    Immobilized Lipase Cartridges (RELiZORB)

    Customize your policy alerts

    Sign up for Centene Policy CP.MP.252 alerts

    Get alerted when Policy CP.MP.252 changes without checking for updates manually.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    Medical necessity criteria and coverage guidance for use of RELiZORB immobilized lipase cartridges with enteral feeding for members of Centene-affiliated health plans.

    Policy Summary
    PayerCentene
    PolicyImmobilized Lipase Cartridges (RELiZORB)
    Policy CodePolicy CP.MP.252
    Change TypeNo material changes
    Effective Date
    Next Review Date
    Key ActionObtain prior authorization demonstrating fecal elastase–confirmed EPI and documentation of PERT optimization or intolerance.
    SourceLink
    POLICY UPDATE CHANGES

    No material clinical or coverage changes in this revision.

    Up to 2/daycartridges allowed for members ≤ 6 months
    Up to 6/daycartridges allowed for members > 6 months
    B4105Referenced billing HCPCS code

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    Coverage Criteria for RELiZORB (Immobilized Lipase Cartridges)

    Initial coverage criteria

    Covered when ALL of the following are met

    Main criteria

    • PERT response or intolerance: Documented failure to achieve or maintain enteral nutrition goals despite optimization of oral pancreatic enzyme replacement therapy (PERT) and nutritional support OR documented contraindication to or intolerance of oral PERT during enteral feeding

      Optimization of oral PERT required unless documented contraindication/intolerance

    • EPI confirmation: Established diagnosis of exocrine pancreatic insufficiency (EPI) confirmed by fecal elastasefecal elastase test result per clinician documentation
    • Daily cartridge quantity limits: For members ≤ six months of age: up to two cartridges per day; For members > six months of age: up to six cartridges per day≤2 or ≤6 cartridges/day based on age

    RELiZORB is intended for use with enteral feeding in individuals who do not secrete sufficient lipase due to exocrine pancreatic insufficiency or related conditions. The policy does not list broad categorical exclusions; rather, coverage is tied to the clinical scenario of insufficient lipase secretion associated with EPI and enteral nutrition. Providers should note that the device is intended to supplement lipase activity during enteral feeding rather than replace standard oral pancreatic enzyme replacement therapy (PERT).

    Requests for RELiZORB for members without documented exocrine pancreatic insufficiency (EPI) confirmed by fecal elastase, or for members who have not had documented failure of or intolerance to optimized oral PERT during enteral feeding, do not meet the medical necessity criteria in this policy. Prior authorization must demonstrate an established EPI diagnosis by fecal elastase and either documented failure to achieve or maintain enteral nutrition goals despite optimized oral PERT and nutritional support, or a documented contraindication/intolerance to oral PERT.

    Coding and Billing

    Referenced HCPCS CodesHCPCS
    B4105In-line cartridge containing digestive enzyme(s) for enteral feeding, each

    Provider Actions, Prior Authorization, and Documentation

    Prior Authorization

    Prior Authorization Required

    Prior authorization is required. Requests must demonstrate the member meets all medical necessity criteria, including a confirmed diagnosis of exocrine pancreatic insufficiency (EPI) by fecal elastase, evidence of enteral feeding, and that the requested quantity aligns with age-based limits.

    • Affected code: B4105 — In-line cartridge containing digestive enzyme(s) for enteral feeding, each
    • Age-based limits: ≤ 6 months: up to 2 cartridges/day; > 6 months: up to 6 cartridges/day
    Step Therapy

    Step Therapy / PERT Optimization

    Prior to approval, documentation must show optimization of oral pancreatic enzyme replacement therapy (PERT) during enteral feeding, or a documented contraindication/intolerance to oral PERT. Optimization means the member has received adequate dosing and administration of oral PERT with continued failure to achieve or maintain enteral nutrition goals despite nutritional support.

    • Optimization must be clearly documented in clinical notes (doses, duration, response)

    Background

    RELiZORB is a single-use, point-of-care, FDA-cleared in-line digestive enzyme cartridge that contains immobilized lipase. The cartridge hydrolyzes triglycerides in enteral formulas into absorbable fatty acids and monoglycerides prior to entry into the gastrointestinal tract, effectively mimicking pancreatic lipase release to enhance fat absorption and utilization in patients with insufficient endogenous lipase secretion.

    Definitions

    Exocrine pancreatic insufficiency (EPI) — definition and clinical consequences
    DefinitionExocrine pancreatic insufficiency (EPI) is a disorder caused by failure of the pancreas to deliver a minimum threshold level of specific pancreatic digestive enzymes to the intestine, leading to maldigestion and malabsorption of nutrients (including macronutrients) and variable nutritional deficiencies.
    Common causesSeen in conditions that impair pancreatic function such as cystic fibrosis and chronic pancreatitis.
    Clinical consequencesFat malabsorption can lead to decreased caloric absorption, impaired utilization of essential fatty acids (including omega-3s), deficiencies of fat-soluble vitamins (A, D, E, K), and increased gastrointestinal symptoms, adversely impacting nutritional status and quality of life.
    Diagnosis thresholdEstablished diagnosis confirmed by fecal elastase (per policy requirement).
    Standard initial therapyPancreatic enzyme replacement therapy (PERT) is considered standard of care once EPI is diagnosed; some patients receiving enteral nutrition may not achieve adequate results with oral PERT alone.
    Policy Summary
    PayerCentene
    PolicyImmobilized Lipase Cartridges (RELiZORB)
    Policy CodePolicy CP.MP.252
    Change TypeNo material changes
    Effective Date
    Next Review Date
    Key ActionObtain prior authorization demonstrating fecal elastase–confirmed EPI and documentation of PERT optimization or intolerance.
    SourceLink
    On This Page
    Coverage Criteria for RELiZORB (Immobilized Lipase Cartridges)Coding and BillingProvider Actions, Prior Authorization, and DocumentationBackgroundDefinitions
  1. If oral PERT is contraindicated or not tolerated, provide clinical rationale and supporting records
  2. Documentation Required

    Required Clinical Documentation

    Documentation must include evidence the member is receiving enteral feeding, confirmation of EPI by fecal elastase testing, records showing PERT optimization or documented contraindication/intolerance, and the requested cartridge quantity with member age to verify dosing limits.

    • Enteral feeding orders or nursing/feeding records
    • Fecal elastase test result confirming EPI
    • Clinical notes detailing PERT trials (dosing, duration, clinical response) or documentation of intolerance/contraindication
    • Requested quantity and member age to confirm ≤2/day if ≤6 months or ≤6/day if >6 months
    Denial Risk

    Denial Triggers

    Requests missing any required medical necessity elements (for example: no documented EPI by fecal elastase, no evidence of enteral feeding, or no documentation of PERT optimization/contraindication) are subject to denial.

    • Common denial reasons: absent fecal elastase confirmation, lack of enteral feeding documentation, no PERT optimization trial or documented contraindication, requested quantity exceeds age-based limits
    RELiZORB — immobilized lipase cartridge
    Device descriptionRELiZORB is a single-use, point-of-care immobilized lipase cartridge indicated for use with enteral feeding systems to hydrolyze fats by converting triglycerides in enteral formulas into absorbable fatty acids and monoglycerides before they enter the gastrointestinal tract.
    Intended effectDesigned to mimic pancreatic lipase release to enhance fat absorption and utilization in individuals who do not secrete sufficient lipase due to pancreatic insufficiency or related conditions.
    Regulatory statusThe only U.S. Food and Drug Administration (FDA)-cleared digestive enzyme cartridge for this purpose (RELiZORB).
    Use with enteral feedingUsed in-line with enteral feeding systems to pre-hydrolyze fats in enteral formulas prior to delivery to the gastrointestinal tract.
    Clinical rationaleClinical evidence demonstrates RELiZORB increases absorption of essential fatty acids and can improve tolerance of enteral nutrition in individuals with EPI who have not achieved adequate results with oral PERT alone.